In turn, TET2 is inhibited by AR in prostate cancer cells through two pathways: AR‐induced inhibition of TET2 expression by the miR‐29 family, and direct binding of AR to the enhancer region of TET2 and inhibition of its transcription [320]. Here, AR is linked to prostate carcinoma.